COMMITTED TO DISCOVERING BEST-IN-CLASS THERAPIES
TO CONQUER INFLAMMATORY and immunologic DISEASES

RAPT Therapeutics to Report Top Line Data from Phase 1b Trial of RPT193 in Atopic Dermatitis

June 13, 2021



« back to news page